Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Conditions

• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Key Dates

Start date

Jul 1, 2022

Status verified

Feb 2026

Primary completion

Jul 31, 2032

Completion

Jul 31, 2032

Study Design

Enrollment

200 participants (estimated)

Primary Outcome Measure

Overall survival [ Time Frame: 5 years ]

Central Contacts

• Astghik Voskanyan, MD
  +374 10 28 38 00
  [email protected]
• Davit Melkonyan
  +374 10 28 38 00
  [email protected]

Locations (3)

Find similar trials in Miami, FL